Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa
First subject dosed in Phase I study to evaluate safety and tolerability of…
Infex Awarded Biomedical Catalyst Grant For COV-X Project
Alderley Park, Cheshire, U.K - Infex Therapeutics, a leading anti-infectives…
COVID-19 Pandemic Triggers Upsurge in MBL Infections
New research has discovered that the ongoing COVID-19 pandemic has triggered a…